FBLG
FibroBiologics, Inc. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website fibrobiologics.com
- Employees(FY) 8
- ISIN US31573L1052
Performance
+29.86%
1W
+3.28%
1M
-15.93%
3M
-61.0%
6M
-61.0%
YTD
-61.0%
1Y
Profile
FibroBiologics, Inc. operates as a clinical-stage cell therapy company that focuses on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs. The company develops CybroCell for degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for treating wound healing. Its early-stage research programs include CYTER915 which is designed to regenerate or reinvigorate production of the thymus and/or spleen; and TCB190 for the treatment of cancers. The company was incorporated in 2021 and is based in Houston, Texas. FibroBiologics, Inc. operates as a subsidiary of Spinalcyte Llc.
Technical Analysis of FBLG 2024-05-10
Overview:
In analyzing the technical indicators for FBLG over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.
Trend Analysis:
- Moving Averages (MA): The 5-day MA has been fluctuating, indicating short-term price ...
Recent News & Updates
- 2024-05-15 04:30
FibroBiologics Announces 2024 Annual Meeting of Stockholders(Globenewswire)
- 2024-05-14 21:54
- 2024-05-14 05:24
FibroBiologics Files 2024 First Quarter Report(Globenewswire)
- 2024-05-06 21:31
- 2024-04-24 20:00
- 2024-04-10 21:31
- 2024-04-03 21:31
- 2024-03-27 21:31
- 2024-03-18 21:31
- 2024-03-12 21:31
- 2024-03-05 20:31
- 2024-02-29 04:44
- 2024-02-19 20:31
- 2024-02-13 09:31
- 2024-02-12 20:31
- 2024-02-08 09:31
- 2024-02-07 20:31
- 2024-02-06 09:31
- 2024-02-05 20:31
- 2024-01-31 10:00
- 2024-01-30 21:00
Page 1 of 1
previousnext